Molecular mechanisms underlying the effects of statins on bone metabolism: an evolving paradigm of statins delivery modalities for bone regeneration.

IF 3.8 3区医学 Q2 PHARMACOLOGY & PHARMACY Pharmacological Reports Pub Date : 2025-06-01 Epub Date: 2025-04-01 DOI:10.1007/s43440-025-00716-7

Randa Mohammed Zaki, Mohamed A M Ali, Mayada Said, Anis Ahmad Chaudhary, Fehmi Boufahja, Obaid Afzal, Abdelghafar M Abu-Elsaoud, Alyaa S Abdel Halim

{"title":"Molecular mechanisms underlying the effects of statins on bone metabolism: an evolving paradigm of statins delivery modalities for bone regeneration.","authors":"Randa Mohammed Zaki, Mohamed A M Ali, Mayada Said, Anis Ahmad Chaudhary, Fehmi Boufahja, Obaid Afzal, Abdelghafar M Abu-Elsaoud, Alyaa S Abdel Halim","doi":"10.1007/s43440-025-00716-7","DOIUrl":null,"url":null,"abstract":"<p><p>Statins, recognized for their lipid-lowering capabilities, have demonstrated osteoanabolic and anti-resorptive effects on bone metabolism. The effects encompass the overexpression of bone morphogenetic proteins, heightened osteoblast activity, and the control of inflammation. Nevertheless, conventional systemic administration of statins has difficulties, including restricted bone bioavailability and possible adverse effects. Recent improvements in targeted and localized drug delivery are revolutionizing the therapeutic landscape for statins in bone applications. This review consolidates existing knowledge regarding the molecular processes by which statins influence bone metabolism and describes novel drug delivery methods such as nano-carriers, biomaterial scaffolds, and controlled-release systems. It seeks to address current knowledge deficiencies and offer insights into how enhanced bioavailability and specificity can optimize the efficiency of statins in bone regeneration. The review integrates molecular insights with novel pharmacological strategies to inform future research and clinical applications, pinpointing critical areas for exploration, such as optimal dose, delivery safety, and clinical efficacy.</p>","PeriodicalId":19947,"journal":{"name":"Pharmacological Reports","volume":" ","pages":"624-644"},"PeriodicalIF":3.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43440-025-00716-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Statins, recognized for their lipid-lowering capabilities, have demonstrated osteoanabolic and anti-resorptive effects on bone metabolism. The effects encompass the overexpression of bone morphogenetic proteins, heightened osteoblast activity, and the control of inflammation. Nevertheless, conventional systemic administration of statins has difficulties, including restricted bone bioavailability and possible adverse effects. Recent improvements in targeted and localized drug delivery are revolutionizing the therapeutic landscape for statins in bone applications. This review consolidates existing knowledge regarding the molecular processes by which statins influence bone metabolism and describes novel drug delivery methods such as nano-carriers, biomaterial scaffolds, and controlled-release systems. It seeks to address current knowledge deficiencies and offer insights into how enhanced bioavailability and specificity can optimize the efficiency of statins in bone regeneration. The review integrates molecular insights with novel pharmacological strategies to inform future research and clinical applications, pinpointing critical areas for exploration, such as optimal dose, delivery safety, and clinical efficacy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

他汀类药物对骨代谢影响的分子机制：他汀类药物用于骨再生的递送方式的演变范式。

他汀类药物以其降脂能力而闻名，已被证明对骨代谢具有骨合成代谢和抗骨吸收作用。这些影响包括骨形态发生蛋白的过度表达、成骨细胞活性的增强和炎症的控制。然而，传统的全身给药他汀类药物有困难，包括限制骨生物利用度和可能的不良反应。最近在靶向和局部药物递送方面的改进正在彻底改变他汀类药物在骨应用中的治疗前景。这篇综述巩固了关于他汀类药物影响骨代谢的分子过程的现有知识，并描述了新的药物递送方法，如纳米载体、生物材料支架和控释系统。它旨在解决目前的知识不足，并提供见解如何提高生物利用度和特异性可以优化他汀类药物在骨再生中的效率。该综述将分子的见解与新的药理学策略结合起来，为未来的研究和临床应用提供信息，指出了探索的关键领域，如最佳剂量、给药安全性和临床疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmacological Reports 医学-药学

CiteScore

8.40

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Pharmacological Reports publishes articles concerning all aspects of pharmacology, dealing with the action of drugs at a cellular and molecular level, and papers on the relationship between molecular structure and biological activity as well as reports on compounds with well-defined chemical structures. Pharmacological Reports is an open forum to disseminate recent developments in: pharmacology, behavioural brain research, evidence-based complementary biochemical pharmacology, medicinal chemistry and biochemistry, drug discovery, neuro-psychopharmacology and biological psychiatry, neuroscience and neuropharmacology, cellular and molecular neuroscience, molecular biology, cell biology, toxicology. Studies of plant extracts are not suitable for Pharmacological Reports.